CA2782469C - Derives azabicyclo [3.1.0] hex- 2 -yl, leur procede de preparation et les compositions pharmaceutiques qui les contiennent - Google Patents

Derives azabicyclo [3.1.0] hex- 2 -yl, leur procede de preparation et les compositions pharmaceutiques qui les contiennent Download PDF

Info

Publication number
CA2782469C
CA2782469C CA2782469A CA2782469A CA2782469C CA 2782469 C CA2782469 C CA 2782469C CA 2782469 A CA2782469 A CA 2782469A CA 2782469 A CA2782469 A CA 2782469A CA 2782469 C CA2782469 C CA 2782469C
Authority
CA
Canada
Prior art keywords
formula
compounds
group
azabicyclo
hex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2782469A
Other languages
English (en)
French (fr)
Other versions
CA2782469A1 (fr
Inventor
Patrick Casara
Anne-Marie Chollet
Alain Dhainaut
Jean-Michel Henlin
Pierre Lestage
Fany Panayi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Les Laboratoires Servier SAS
Original Assignee
Les Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42711699&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2782469(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Les Laboratoires Servier SAS filed Critical Les Laboratoires Servier SAS
Publication of CA2782469A1 publication Critical patent/CA2782469A1/fr
Application granted granted Critical
Publication of CA2782469C publication Critical patent/CA2782469C/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2782469A 2009-12-09 2010-12-08 Derives azabicyclo [3.1.0] hex- 2 -yl, leur procede de preparation et les compositions pharmaceutiques qui les contiennent Expired - Fee Related CA2782469C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0905953A FR2953521B1 (fr) 2009-12-09 2009-12-09 Nouveaux derives azabicyclo[3.1.0]hex-2-yl, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR09.05953 2009-12-09
PCT/FR2010/000823 WO2011070253A1 (fr) 2009-12-09 2010-12-08 Derives azabicyclo [3.1.0] hex- 2 -yl, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (2)

Publication Number Publication Date
CA2782469A1 CA2782469A1 (fr) 2011-06-16
CA2782469C true CA2782469C (fr) 2014-04-08

Family

ID=42711699

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2782469A Expired - Fee Related CA2782469C (fr) 2009-12-09 2010-12-08 Derives azabicyclo [3.1.0] hex- 2 -yl, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Country Status (32)

Country Link
US (1) US20120283245A1 (Direct)
EP (1) EP2509947A1 (Direct)
JP (1) JP2013513589A (Direct)
KR (1) KR20120102763A (Direct)
CN (1) CN102652127A (Direct)
AP (1) AP2012006352A0 (Direct)
AR (1) AR079265A1 (Direct)
AU (1) AU2010329762B2 (Direct)
BR (1) BR112012013666A2 (Direct)
CA (1) CA2782469C (Direct)
CL (1) CL2012001479A1 (Direct)
CO (1) CO6541535A2 (Direct)
CR (1) CR20120286A (Direct)
CU (1) CU20120091A7 (Direct)
EA (1) EA201200849A1 (Direct)
EC (1) ECSP12011950A (Direct)
FR (1) FR2953521B1 (Direct)
GE (1) GEP20156227B (Direct)
IN (1) IN2012DN04966A (Direct)
MA (1) MA33882B1 (Direct)
MX (1) MX2012006578A (Direct)
NI (1) NI201200099A (Direct)
PE (1) PE20121475A1 (Direct)
PH (1) PH12012501053A1 (Direct)
SA (1) SA110320011B1 (Direct)
SG (1) SG181082A1 (Direct)
TN (1) TN2012000267A1 (Direct)
TW (1) TW201200499A (Direct)
UA (1) UA102950C2 (Direct)
UY (1) UY33072A (Direct)
WO (1) WO2011070253A1 (Direct)
ZA (1) ZA201203943B (Direct)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015032966A1 (en) * 2013-09-09 2015-03-12 Sanofi An h3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2866647B1 (fr) * 2004-02-20 2006-10-27 Servier Lab Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB0507680D0 (en) * 2005-04-15 2005-05-25 Glaxo Group Ltd Compounds
CA2630270A1 (en) * 2005-11-30 2007-06-07 F. Hoffmann-La Roche Ag 5-substituted indole-2-carboxamide derivatives

Also Published As

Publication number Publication date
IN2012DN04966A (Direct) 2015-09-25
KR20120102763A (ko) 2012-09-18
CA2782469A1 (fr) 2011-06-16
PH12012501053A1 (en) 2013-02-04
AR079265A1 (es) 2012-01-04
WO2011070253A1 (fr) 2011-06-16
GEP20156227B (en) 2015-01-26
AU2010329762B2 (en) 2013-10-03
TW201200499A (en) 2012-01-01
US20120283245A1 (en) 2012-11-08
BR112012013666A2 (pt) 2016-04-19
CU20120091A7 (es) 2012-07-31
UY33072A (es) 2011-05-31
AU2010329762A1 (en) 2012-06-21
AP2012006352A0 (en) 2012-08-31
SG181082A1 (en) 2012-07-30
CR20120286A (es) 2012-08-20
JP2013513589A (ja) 2013-04-22
FR2953521A1 (fr) 2011-06-10
EP2509947A1 (fr) 2012-10-17
ECSP12011950A (es) 2012-07-31
UA102950C2 (ru) 2013-08-27
CO6541535A2 (es) 2012-10-16
ZA201203943B (en) 2013-08-28
TN2012000267A1 (fr) 2013-12-12
MA33882B1 (fr) 2013-01-02
MX2012006578A (es) 2012-06-25
SA110320011B1 (ar) 2013-10-01
FR2953521B1 (fr) 2011-11-18
CN102652127A (zh) 2012-08-29
EA201200849A1 (ru) 2013-01-30
NI201200099A (es) 2012-11-09
WO2011070253A8 (fr) 2012-08-02
CL2012001479A1 (es) 2013-02-08
PE20121475A1 (es) 2012-10-20

Similar Documents

Publication Publication Date Title
CA2555216C (fr) Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP1275647B1 (fr) Dérivés d'octahydro-2H-pyrido[1,2-a]pyrazine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
WO2011070251A1 (fr) Nouveaux derives du type hexahydrocyclopenta[b]pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2782469C (fr) Derives azabicyclo [3.1.0] hex- 2 -yl, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP1241169A1 (fr) Dérivés d'isoindoloindolone, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
FR2976286A1 (fr) 4-{3-[trans-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide, son procede de preparation et les compositions pharmaceutiques qui le contiennent
FR2822153A1 (fr) Nouveaux derives d'indenoindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2668527A1 (fr) Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP2332910B1 (fr) Nouveaux dérivés azabicyclo[3.2.0] hept-3-yl, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
WO2011070252A1 (fr) Derives d'azabicyclo[3.2.0]hept-6-yle comme antagonistes des recepteurs histaminergiques de type h3
WO2006120348A1 (fr) Nouveaux derives de phenylpyridinylpiperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2006125887A1 (fr) Composes derives de 5h-pyrido[4,3-b]indole et leurs utilisations comme medicament pour traiter les maladies neurodegeneratives a polyglutamines
WO2014087110A1 (fr) Procédé de synthèse d'un sel d'addition a un acide pharmaceutiquement acceptable du 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide, ainsi que les formes cristallines associees
FR2918372A1 (fr) Nouveaux derives naphtaleniques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent
HK1139679A (zh) 新的氮杂双环化合物、它们的制备方法以及含有它们的药用组合物
HK1175460A (en) Azabicyclo[3.1.0]hex-2-yl derivatives, method for preparing same, and pharmaceutical compositions containing same

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20151208